Remove 2030 Remove Healthcare Remove Side effects
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential side effects.

article thumbnail

Lilly has a new blockbuster

World of DTC Marketing

Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. According to Lilly side, the effects include “Mounjaro may cause tumors in the thyroid, including thyroid cancer and Inflammation of the pancreas (pancreatitis).”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top healthcare digital transformation trends of 2023

Clarify Health

Despite the rapid adoption of digital technology in other industries, healthcare has been a bit slower to transform. This shift in healthcare focuses on treating patients more like consumers , giving them more control and options in their healthcare decisions.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . It has to persuade patients to sign up for some heinous side effects.

article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

article thumbnail

The future of pharma depends on its employees

World of DTC Marketing

By 2030, low retention will, on average, cost the US $430 billion annually. I do not doubt that eventually, Congress will act to bring down rising healthcare costs, and that effect could be profound on big pharma. Employee retention rates hit a record low in March 2020. Good retention can maximize company profits up to 4 times.

Pharma 215
article thumbnail

Improving patient access and healthcare literacy [PODCAST]

Clarivate

Grace tells us about her experience as a physician and discusses healthcare literacy and education at the point of care. In 2017, the same year the SDGs came into effect, the United Nations found that less than half of the global population was covered by essential health services. Supporting patients at the point of care.